Startup Valuations, Biotech’s Crunch & AI’s Massive TAM | E2147
It’s another blockbuster panel of insiders, as Alex sits down with Astasia Myers from Felicis, Matt Turck from First Mark Capital, and D.A. Wallach of Time BioVentures. AI is reshaping early-stage investing, with startups raising record-setting rounds adn chasing $100B+ markets. Meanwhile, biotech faces a “Great Depression” as public markets stay shut, putting added pressure on private capital. In healthcare, AI-powered virtual doctors promise to bring world-class medical advice to everyone, while fertility tech could revolutionize IVF by automating embryo handling and slashing costs. Hear our VC experts exclusive thoughts on these trends and much more!
Key Points
- AI is poised to revolutionize healthcare by providing high-quality, gold-standard medical knowledge to everyone, potentially putting the world's greatest doctor at the fingertips of every person on earth.
- The venture capital market is seeing a shift towards smaller founding teams and more efficient startups leveraging AI tools, enabling them to achieve more with less and potentially increase their runway by reducing human resource expenditures.
- Despite challenges in the biotech sector, there is optimism around innovations such as the automation of IVF processes, which could democratize access to fertility treatments and significantly impact global birth rates.
Chapters
0:00 | |
0:23 | |
0:53 | |
1:16 | |
2:21 | |
12:16 | |
17:08 | |
20:34 | |
21:46 | |
24:29 | |
25:14 | |
29:31 | |
30:45 | |
35:37 | |
43:08 | |
51:21 | |
56:28 | |
1:01:51 | |
1:06:43 | |
1:09:10 | |
1:12:27 | |
1:15:51 | |
1:16:14 |
Transcript
Loading transcript...
- / -